Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML
September 9th 2021The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.
Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward
September 8th 2021The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.
Novel, Emerging Approaches Set the Stage for Advancement in cGVHD
September 8th 2021In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.
Novel Combos Are Shaking Up the CLL Landscape
The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications.
Tisagenlecleucel Maintains Efficacy in Real-World Setting
Early results from a prospective postmarketing assessment showed that tisagenlecleucel induced responses similar to those seen in pivotal trials for children and adolescents with B-cell acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.
Update Spotlights Tisagenlecleucel Developments in DLBCL
Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.
Checkpoint Inhibition Before HSCT Improves PFS Without Increasing Toxicity in R/R Hodgkin Lymphoma
The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.
Dr. Maloney on the Registry for Real World Data of CAR T-Cell Therapy in ALL
September 13th 2019David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.
Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
Reducing or interrupting duvelisib treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival compared with ofatumumab while producing rapid and durable responses in heavily pretreated patients.